Division of Biometrics IV, Office of Biometrics/OTS/CDER/FDA, Silver Spring, MD 20993-0002, USA.
Stat Med. 2010 May 10;29(10):1107-13. doi: 10.1002/sim.3871.
To maintain the interpretability of the effect of experimental treatment (EXP) obtained from a noninferiority trial, current statistical approaches often require the constancy assumption. This assumption typically requires that the control treatment effect in the population of the active control trial is the same as its effect presented in the population of the historical trial. To prevent constancy assumption violation, clinical trial sponsors were recommended to make sure that the design of the active control trial is as close to the design of the historical trial as possible. However, these rigorous requirements are rarely fulfilled in practice. The inevitable discrepancies between the historical trial and the active control trial have led to debates on many controversial issues. Without support from a well-developed quantitative method to determine the impact of the discrepancies on the constancy assumption violation, a correct judgment seems difficult. In this paper, we present a covariate-adjustment generalized linear regression model approach to achieve two goals: (1) to quantify the impact of population difference between the historical trial and the active control trial on the degree of constancy assumption violation and (2) to redefine the active control treatment effect in the active control trial population if the quantification suggests an unacceptable violation. Through achieving goal (1), we examine whether or not a population difference leads to an unacceptable violation. Through achieving goal (2), we redefine the noninferiority margin if the violation is unacceptable. This approach allows us to correctly determine the effect of EXP in the noninferiority trial population when constancy assumption is violated due to the population difference. We illustrate the covariate-adjustment approach through a case study.
为了保持非劣效性试验中实验治疗(EXP)效果的可解释性,当前的统计方法通常需要常数假设。该假设通常要求活性对照试验人群中的对照处理效果与其在历史试验人群中的效果相同。为了防止违反常数假设,临床试验发起者被建议确保活性对照试验的设计尽可能接近历史试验的设计。然而,这些严格的要求在实践中很少得到满足。历史试验和活性对照试验之间不可避免的差异导致了许多有争议问题的争论。如果没有一个完善的定量方法来确定差异对常数假设违反的影响,正确的判断似乎很难。在本文中,我们提出了一种协变量调整的广义线性回归模型方法,以实现两个目标:(1)量化历史试验和活性对照试验人群之间的差异对常数假设违反程度的影响;(2)如果量化结果表明违反不可接受,则重新定义活性对照试验人群中的活性对照治疗效果。通过实现目标 1,我们检验人群差异是否导致不可接受的违反。通过实现目标 2,如果违反不可接受,我们重新定义非劣效性边界。当由于人群差异导致常数假设违反时,这种方法允许我们在非劣效性试验人群中正确确定 EXP 的效果。我们通过一个案例研究来说明协变量调整方法。